echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > COVID-19 has been linked to a significant increase in type 1 diabetes in children – up to 72%

    COVID-19 has been linked to a significant increase in type 1 diabetes in children – up to 72%

    • Last Update: 2022-10-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

                             

    According to a new study that analyzed the electronic health records of more than 1 million patients aged 18 and under, children who were at much
    higher risk of contracting type 1 diabetes (T1D) with novel coronavirus pneumonia.


    Researchers at Case Western Reserve University School of Medicine report that children and adolescents infected with COVID-19 are more likely to develop T1D
    within 6 months of diagnosis.


    Type 1 diabetes was previously known as insulin-dependent or juvenile diabetes
    .


    "Type 1 diabetes is considered an autoimmune disease," said Pamela Davis, the study's corresponding author, who is also a Distinguished University Professor at Case Western Reserve Medical School and a research professor
    at Arline H.


    The research team analyzed the unidentified electronic health records
    of nearly 1.


    The study population was further divided into two groups: patients under 9 years of age and patients aged 10-18 years
    .


    Results of the study

    In more than 571,000 pediatric patients, the researchers found:

    • Within 6 months of SARS-CoV2 infection, 123 patients (0.


    • At 1, 3, and 6 months after infection, SARS-CoV2 infected people are at much
      greater risk of diagnosing T1D than in patients with non-COVID respiratory infections.


    "Families with children at high risk of developing type 1 diabetes should be particularly vigilant for symptoms of diabetes following COVID, and pediatricians should be wary of the influx of new cases of type 1 diabetes, especially since the omegalon variant of COVID spreads so rapidly
    among children," Davis said.


    Corresponding author Xu Rong, a professor of biomedical informatics at the School of Medicine and director of the Center for Artificial Intelligence in Drug Development, said further research is needed to investigate whether the increased risk of new T1D in vulnerable children after SARS-CoV2 infection persists, and how to treat COVID-19-related T1D
    in children.


    Professor Xu said: "We are also studying the possible changes
    in the development of type 2 diabetes in children after SARS-CoV2 infection.


    T1D is most common in children, and type 2 diabetes (T2D) is known as "adult-onset diabetes" and develops over time, usually when a patient becomes resistant to the effects of insulin, and then when the pancreas stops making enough insulin, according to the Centers for
    Disease Control.


    Association of SARS-CoV-2 Infection With New-Onset Type 1 Diabetes Among Pediatric Patients From 2020 to 2021" by Ellen K.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.